Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bioequivalence of Two Survodutide (BI 456906) Formulations Via Subcutaneous Administration After Multiple Doses (an Open-label, Randomised, Multiple-dose, Crossover Trial)

NCT07407348 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT07407348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07407348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bioequivalence of Two Survodutide (BI 456906) Formulations Via Subcutaneous Administration After Multiple Doses (an Open-label, Randomised, Multiple-dose, Crossover Trial)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 11, 2026
Completion date
March 2, 2027
Enrollment
80 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy, obesity, overweight